10% owner at Inhibrx Biosciences, BridgeBio Pharma and Acuren
Earlier: APi Group, Inhibrx, Standard Biotools, RayzeBio, 4D Molecular Therapeutics, Roivant Sciences, Frazier Lifesciences Acquisition, Rallybio, Amylyx Pharmaceuticals, PROCEPT BioRobotics, Ginkgo Bioworks Holdings, FIGS, Adaptive Biotechnologies, Zentalis Pharmaceuticals, Arbutus Biopharma, Axovant Gene Therapies, Myovant Sciences, Urovant Sciences, First Data, Editas Medicine and Wayfair
As reported after the latest Form 3, 4 or 5 at each company.
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Inhibrx Biosciences INXB | Common Stock | See Explanation of Responses | 102,864 | Oct 7, 2025 · Filing · EDGAR |
| Inhibrx Biosciences INXB | Warrants (right to buy) exercise $0.00, into Common Stock | See Explanation of Responses | 259,692 | May 29, 2024 · Filing · EDGAR |
| BridgeBio Pharma BBIO | Common Stock | See Explanation of Responses | 18,555,375 | Jun 27, 2025 · Filing · EDGAR |
| Acuren TIC | Common Stock | See Explanation of Responses | 11,338,800 | Feb 14, 2025 · Filing · EDGAR |
| APi Group | Common Stock | See Explanation of Responses | 27,032,516 | Jun 17, 2024 · Filing · EDGAR |
| Standard Biotools | Common Stock | See Explanation of Responses | 19,354,860 | Mar 18, 2024 · Filing · EDGAR |
| 4D Molecular Therapeutics | Common Stock | See Explanation Responses | 4,247,914 | Jan 4, 2024 · Filing · EDGAR |
| Roivant Sciences | Common Shares | See Explanation of Responses | 12,884,307 | Jun 22, 2023 · Filing · EDGAR |
| Frazier Lifesciences Acquisition | Common Stock | See Explanation of Responses | 1,211,582 | Nov 2, 2022 · Filing · EDGAR |
| Rallybio | Common Stock | See Explanation Responses | 4,194,777 | Jul 29, 2021 · Filing · EDGAR |
| Rallybio | Pre-Funded Warrants to Purchase Common Stock exercise $0.00, into Common Stock | See Explanation of Responses | 3,333,388 | Nov 15, 2022 · Filing · EDGAR |
| Amylyx Pharmaceuticals | Common Stock | See Explanation of Responses | 1,850,940 | Sep 9, 2022 · Filing · EDGAR |
| PROCEPT BioRobotics | Common Stock | See Explanation of Responses | 298,205 | Mar 18, 2022 · Filing · EDGAR |
| Ginkgo Bioworks Holdings | Class A Common Stock | See Explanation of Responses | 51,055,144 | Mar 2, 2022 · Filing · EDGAR |
| Ginkgo Bioworks Holdings | Class C Common Stock into Class A Common Stock | See Explanation of Responses | 288,000,000 | Mar 2, 2022 · Filing · EDGAR |
| FIGS | Class A Common Stock | See Explanation Responses | 14,742,689 | Sep 3, 2021 · Filing · EDGAR |
| Adaptive Biotechnologies | Common Stock | See explanation of responses | 29,993,708 | Dec 14, 2020 · Filing · EDGAR |
| Zentalis Pharmaceuticals | Common Stock | See Explanation of Responses | 3,943,284 | Dec 1, 2020 · Filing · EDGAR |
| Arbutus Biopharma | Common Shares | See Explanation of Responses | 16,013,540 | Jul 8, 2016 · Filing · EDGAR |
| Axovant Gene Therapies | Common Shares, par value $0.00001 per share | See Footnotes | 105,952,381 | Mar 18, 2019 · Filing · EDGAR |
| Axovant Gene Therapies | Common Shares | See Explanation of Responses | 75,000,000 | Jul 8, 2016 · Filing · EDGAR |
| Myovant Sciences | Common Shares, $0.000017727 par value per share | See Footnotes | 40,765,599 | Jun 4, 2019 · Filing · EDGAR |
| Myovant Sciences | Common Shares, $0.000017727 par value per share | See Explanation of Responses | 38,341,357 | Apr 2, 2018 · Filing · EDGAR |
| Urovant Sciences | Common Shares, par value $0.000037453 per share | See Footnotes | 22,860,013 | Jun 19, 2019 · Filing · EDGAR |
| Urovant Sciences | Common Shares, $0.000037453 par value per share | See Explanation of Responses | 20,025,098 | Sep 26, 2018 · Filing · EDGAR |
| First Data | Class A Common Stock | Directly | 5,874,105 | Apr 13, 2016 · Filing · EDGAR |
| First Data | Class A Common Stock | See explanation of responses | 21,750,064 | Apr 13, 2016 · Filing · EDGAR |
| Editas Medicine | Common Stock | Directly | 266,782 | Feb 8, 2015 · Filing · EDGAR |
| Editas Medicine | Common Stock | See explanation of responses | 2,729,808 | Feb 8, 2015 · Filing · EDGAR |
| Wayfair | Class A Common Stock | Directly | 538,711 | Nov 20, 2014 · Filing · EDGAR |
| Wayfair | Class A Common Stock | See Explanation of Responses | 1,791,536 | Nov 20, 2014 · Filing · EDGAR |
| Wayfair | Class B Common Stock into Class A Common Stock | See explanation of responses | 1,270,986 | Oct 1, 2014 · Filing · EDGAR |
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q4 2025 | $11.3M | — | — |
| Q2 2025 | $154M | — | — |
| Q1 2025 | $107M | $107M | — |
| Q2 2024 | $148.9M | — | — |
| Q1 2024 | $625.6M | $213.7M | — |
| Q3 2023 | $52.5M | — | $59.9M |
| Q2 2023 | $128.7M | — | $13.6M |
| Q4 2022 | — | — | $48.5M |
| Q3 2022 | $41.7M | Not machine-readable | — |
| Q1 2022 | $37.3M | Not machine-readable | $43.7M |
| Q3 2021 | $9.4M | Not machine-readable | $24.5M |
| Q4 2020 | $204.7M | Not machine-readable | $25.3M |
| Q3 2020 | — | — | $6M |
| Q2 2020 | — | — | $13.1M |
| Q1 2020 | $122.7M | Not machine-readable | — |
| Q3 2019 | — | — | $5M |
| Q2 2019 | — | — | $201.1M |
| Q1 2019 | — | — | $10M |
| Q4 2018 | — | — | $47.5M |
| Q2 2018 | — | — | $47.5M |
| Q1 2015 | — | — | $32.7M |
| Q4 2014 | — | — | $19.6M |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| BridgeBio Pharma BBIO · Citigroup · No 10b5-1 plan stated · 1 notice | ||||
| Jan 31, 2025 | 3,065,616 · ~$107M | Jan 31, 2025 | Sold as noticed Sold 3,065,616 at $34.90 on Jan 31 · $107M Form 4 | Filing · EDGAR |
| APi Group · J.P. Morgan Securities · No 10b5-1 plan stated · 1 notice | ||||
| Jan 2, 2024 | 6,500,000 · ~$213.7M | Jan 2, 2024 | Sold as noticed Sold 6,564,755 in 5 sales, Jan 2 to Mar 5 · $205.7M Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Sales without a matching Form 144 · 43 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Sold without notice Inhibrx Biosciences (INXB): Sold 25,042 at $32.25 on Oct 7, 2025 · $808K | Filing · EDGAR |
| — | — | — | Sold without notice Inhibrx Biosciences (INXB): Sold 16,315 at $32.25 on Oct 7, 2025 · $526K | Filing · EDGAR |
| — | — | — | Sold without notice Inhibrx Biosciences (INXB): Sold 308,643 at $32.25 on Oct 7, 2025 · $10M | Filing · EDGAR |
| — | — | — | Sold without notice BridgeBio Pharma (BBIO): Sold 3,500,000 at $44.00 on Jun 27, 2025 · $154M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 39,032 at $38.15 on Jun 17, 2024 · $1.5M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 1,912,750 at $38.15 on Jun 17, 2024 · $73M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 39,032 at $38.15 on Jun 17, 2024 · $1.5M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 1,912,750 at $38.15 on Jun 17, 2024 · $73M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 60,772 at $34.25 on Mar 5, 2024 · $2.1M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 2,977,845 at $34.25 on Mar 5, 2024 · $102M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 2,977,845 at $34.25 on Mar 5, 2024 · $102M | Filing · EDGAR |
| — | — | — | Sold without notice 4D Molecular Therapeutics: Sold 540,000 at $19.53 on Jan 4, 2024 · $10.5M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 195,200 at $31.30 on Jan 2, 2024 · $6.1M | Filing · EDGAR |
| — | — | — | Sold without notice APi Group: Sold 6,300,817 at $31.30 on Jan 2, 2024 · $197.2M | Filing · EDGAR |
| — | — | — | Sold without notice BridgeBio Pharma (BBIO): Sold 1,500,000 at $35.00 on Jul 18, 2023 · $52.5M | Filing · EDGAR |
| — | — | — | Sold without notice Roivant Sciences: Sold 2,226,195 at $9.90 on Jun 22, 2023 · $22M | Filing · EDGAR |
| — | — | — | Sold without notice Roivant Sciences: Sold 5,236,006 at $9.90 on Jun 22, 2023 · $51.8M | Filing · EDGAR |
| — | — | — | Sold without notice Roivant Sciences: Sold 5,427,043 at $9.90 on Jun 22, 2023 · $53.7M | Filing · EDGAR |
| — | — | — | Sold without notice Roivant Sciences: Sold 110,756 at $9.90 on Jun 22, 2023 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 3,142 at $31.44 on Sep 9, 2022 · $99K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 73,886 at $30.90 on Sep 9, 2022 · $2.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 147,502 at $29.87 on Sep 9, 2022 · $4.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 6,654 at $31.44 on Sep 9, 2022 · $209K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 156,463 at $30.90 on Sep 9, 2022 · $4.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 312,353 at $29.87 on Sep 9, 2022 · $9.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 52,466 at $32.23 on Sep 8, 2022 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 7,554 at $30.59 on Sep 8, 2022 · $231K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 75,096 at $29.14 on Sep 8, 2022 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 51,298 at $28.16 on Sep 8, 2022 · $1.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 38,116 at $27.28 on Sep 8, 2022 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 111,102 at $32.23 on Sep 8, 2022 · $3.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 15,996 at $30.59 on Sep 8, 2022 · $489K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 159,026 at $29.14 on Sep 8, 2022 · $4.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 108,631 at $28.16 on Sep 8, 2022 · $3.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amylyx Pharmaceuticals: Sold 80,715 at $27.28 on Sep 8, 2022 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable PROCEPT BioRobotics: Sold 101,795 at $29.90 on Mar 18, 2022 · $3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable PROCEPT BioRobotics: Sold 1,147,205 at $29.90 on Mar 18, 2022 · $34.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable FIGS: Sold 42,413 at $44.92 on Sep 3, 2021 · $1.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable FIGS: Sold 157,587 at $47.28 on Sep 2, 2021 · $7.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptive Biotechnologies: Sold 1,000,000 at $55.65 on Dec 14, 2020 · $55.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Zentalis Pharmaceuticals: Sold 500,000 at $50.50 on Dec 1, 2020 · $25.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptive Biotechnologies: Sold 2,500,000 at $49.52 on Nov 11, 2020 · $123.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptive Biotechnologies: Sold 4,912,899 at $24.98 on Jan 28, 2020 · $122.7M | Filing · EDGAR |
Each Form 3, 4 and 5 transaction in plain words, newest first.
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | Open-market or private sale | −308,643 | $32.25 | $10M | 1,267,823 See Explanation of Responses | Filing · EDGAR |
| Oct 7, 2025 | Open-market or private sale | −16,315 | $32.25 | $526K | 67,018 See Explanation of Responses | Filing · EDGAR |
| Oct 7, 2025 | Open-market or private sale | −25,042 | $32.25 | $808K | 102,864 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 27, 2025 | Open-market or private sale | −3,500,000 | $44.00 | $154M | 18,555,375 See Explanation of Responses | Filing · EDGAR |
| Jan 31, 2025 | Open-market or private sale | −3,065,616 | $34.90 | $107M | 22,055,375 See Explanation of Responses | Filing · EDGAR |
| Jul 18, 2023 | Open-market or private sale | −1,500,000 | $35.00 | $52.5M | 25,120,991 See Explanation of Responses | Filing · EDGAR |
| Jun 27, 2019 | Derivative converted | +11,736,137 | $0.00 | $12K | 11,736,137 See Explanation of Responses | Filing · EDGAR |
| Jun 27, 2019 | Derivative converted | +10,178,954 | $0.00 | $10K | 21,915,091 See Explanation of Responses | Filing · EDGAR |
| Jun 27, 2019 | Open-market or private purchase | +4,705,900 | $17.00 | $80M | 26,620,991 See Explanation of Responses | Filing · EDGAR |
| Jun 27, 2019 | Derivative converted Series C Preferred Units | −51,781,276 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Jun 27, 2019 | Derivative converted Series D Preferred Units | −50,446,451 | 0 See Explanation of Responses | Filing · EDGAR |
No transactions in the filings read; Form 144 notices are listed above.
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Open-market or private sale | −1,912,750 | $38.15 | $73M | 0 See Explanation of Responses | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private sale | −39,032 | $38.15 | $1.5M | 0 See Explanation of Responses | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private sale | −1,912,750 | $38.15 | $73M | 0 See Explanation of Responses | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private sale | −39,032 | $38.15 | $1.5M | 0 See Explanation of Responses | Filing · EDGAR |
| Mar 5, 2024 | Open-market or private sale | −2,977,845 | $34.25 | $102M | 1,912,750 See Explanation of Responses | Filing · EDGAR |
| Mar 5, 2024 | Open-market or private sale | −60,772 | $34.25 | $2.1M | 39,032 See Explanation of Responses | Filing · EDGAR |
| Mar 5, 2024 | Open-market or private sale | −2,977,845 | $34.25 | $102M | 1,912,750 See Explanation of Responses | Filing · EDGAR |
| Mar 5, 2024 | Open-market or private sale | −60,772 | $34.25 | $2.1M | 39,032 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Derivative converted | +8,036,862 | $24.60 | $197.7M | 8,874,334 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Derivative converted | +164,016 | $24.60 | $4M | 181,104 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Other acquisition or disposition (see the filing) | −3,983,739 | $36.90 | $147M | 4,890,595 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Other acquisition or disposition (see the filing) | −81,300 | $36.90 | $3M | 99,804 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Derivative converted 5.5% Series B Perpetual Convertible Preferred Stock | −196,000 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Feb 28, 2024 | Derivative converted 5.5% Series B Perpetual Convertible Preferred Stock | −4,000 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Feb 28, 2024 | Derivative converted | +8,036,862 | $24.60 | $197.7M | 8,874,334 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Derivative converted | +164,016 | $24.60 | $4M | 181,104 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Other acquisition or disposition (see the filing) | −3,983,739 | $36.90 | $147M | 4,890,595 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Other acquisition or disposition (see the filing) | −81,300 | $36.90 | $3M | 99,804 See Explanation of Responses | Filing · EDGAR |
| Feb 28, 2024 | Derivative converted 5.5% Series B Perpetual Convertible Preferred Stock | −196,000 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Feb 28, 2024 | Derivative converted 5.5% Series B Perpetual Convertible Preferred Stock | −4,000 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Jan 2, 2024 | Open-market or private sale | −6,300,817 | $31.30 | $197.2M | 27,032,516 See Explanation of Responses | Filing · EDGAR |
| Jan 2, 2024 | Open-market or private sale | −195,200 | $31.30 | $6.1M | 837,472 See Explanation of Responses | Filing · EDGAR |
| Jan 2, 2024 | Open-market or private sale | −3,983 | $31.30 | $125K | 17,088 See Explanation of Responses | Filing · EDGAR |
| Jan 2, 2024 | Open-market or private sale | −6,300,817 | $31.30 | $197.2M | 27,032,516 See Explanation of Responses | Filing · EDGAR |
| Jan 2, 2024 | Open-market or private sale | −195,200 | $31.30 | $6.1M | 837,472 See Explanation of Responses | Filing · EDGAR |
| Jan 2, 2024 | Open-market or private sale | −3,983 | $31.30 | $125K | 17,088 See Explanation of Responses | Filing · EDGAR |
| Jan 3, 2022 | Open-market or private purchase 5.5% Series B Perpetual Convertible Preferred Stock | +196,000 | $1,000.00 | $196M | 196,000 Held by Viking Global Equities Master Ltd. | Filing · EDGAR |
| Jan 3, 2022 | Open-market or private purchase 5.5% Series B Perpetual Convertible Preferred Stock | +4,000 | $1,000.00 | $4M | 4,000 Held by Viking Global Equities II LP | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 30, 2024 | Other acquisition or disposition (see the filing) | −6,305,866 | $30.00 | $189.2M | 0 See Explanation of Responses | Filing · EDGAR |
| May 30, 2024 | Other acquisition or disposition (see the filing) | −333,333 | $30.00 | $10M | 0 See Explanation of Responses | Filing · EDGAR |
| May 30, 2024 | Other acquisition or disposition (see the filing) | −511,627 | $30.00 | $15.3M | 0 See Explanation of Responses | Filing · EDGAR |
| May 30, 2024 | Other acquisition or disposition (see the filing) Warrants (right to buy) | −1,038,765 | $30.00 | $31.2M | 0 See Explanation of Responses | Filing · EDGAR |
| Aug 28, 2023 | Open-market or private purchase | +511,627 | $19.35 | $9.9M | 511,627 See Explanation of Responses | Filing · EDGAR |
| Aug 28, 2023 | Open-market or private purchase Warrants (right to buy) | +1,038,765 | $19.35 | $20.1M | 1,038,765 See Explanation of Responses | Filing · EDGAR |
| Oct 7, 2022 | Open-market or private purchase | +1,000,000 | $30.00 | $30M | 2,427,307 See Explanation of Responses | Filing · EDGAR |
| Oct 7, 2022 | Open-market or private purchase | +333,333 | $30.00 | $10M | 333,333 See Explanation of Responses | Filing · EDGAR |
| Aug 26, 2020 | Open-market or private purchase | +80,219 | $18.84 | $1.5M | 1,327,307 See Explanation of Responses | Filing · EDGAR |
| Aug 26, 2020 | Open-market or private purchase | +100,000 | $18.99 | $1.9M | 1,427,307 See Explanation of Responses | Filing · EDGAR |
| Aug 25, 2020 | Open-market or private purchase | +14,825 | $19.23 | $285K | 1,176,609 See Explanation of Responses | Filing · EDGAR |
| Aug 25, 2020 | Open-market or private purchase | +70,479 | $19.39 | $1.4M | 1,247,088 See Explanation of Responses | Filing · EDGAR |
| Aug 24, 2020 | Open-market or private purchase | +46,161 | $19.43 | $897K | 1,161,784 See Explanation of Responses | Filing · EDGAR |
No transactions in the filings read; Form 144 notices are listed above.
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 26, 2024 | Other acquisition or disposition (see the filing) | −4,899,144 | $62.50 | $306.2M | 0 See Explanation of Responses | Filing · EDGAR |
| Feb 26, 2024 | Other acquisition or disposition (see the filing) | −1,743,556 | $62.50 | $109M | 0 See Explanation of Responses | Filing · EDGAR |
| Feb 26, 2024 | Other acquisition or disposition (see the filing) | −4,899,144 | $62.50 | $306.2M | 0 See Explanation of Responses | Filing · EDGAR |
| Feb 26, 2024 | Other acquisition or disposition (see the filing) | −1,743,556 | $62.50 | $109M | 0 See Explanation of Responses | Filing · EDGAR |
| Sep 19, 2023 | Derivative converted | +864,509 | 864,509 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted | +494,687 | 1,359,196 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted | +2,609,392 | 3,968,588 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Open-market or private purchase | +930,556 | $18.00 | $16.8M | 4,899,144 See Explanation of Responses | Filing · EDGAR |
| Sep 19, 2023 | Derivative converted | +1,285,223 | 1,285,223 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Open-market or private purchase | +458,333 | $18.00 | $8.2M | 1,743,556 See Explanation of Responses | Filing · EDGAR |
| Sep 19, 2023 | Derivative converted Series B Convertible Preferred Stock | −864,509 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series C Convertible Preferred Stock | −432,254 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series D Convertible Preferred Stock | −2,609,392 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series D Convertible Preferred Stock | −1,285,223 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted | +864,509 | 864,509 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted | +494,687 | 1,359,196 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted | +2,609,392 | 3,968,588 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Open-market or private purchase | +930,556 | $18.00 | $16.8M | 4,899,144 See Explanation of Responses | Filing · EDGAR |
| Sep 19, 2023 | Derivative converted | +1,285,223 | 1,285,223 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Open-market or private purchase | +458,333 | $18.00 | $8.2M | 1,743,556 See Explanation of Responses | Filing · EDGAR |
| Sep 19, 2023 | Derivative converted Series B Convertible Preferred Stock | −864,509 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series C Convertible Preferred Stock | −432,254 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series D Convertible Preferred Stock | −2,609,392 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 19, 2023 | Derivative converted Series D Convertible Preferred Stock | −1,285,223 | 0 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 4, 2024 | Open-market or private sale | −540,000 | $19.53 | $10.5M | 4,247,914 See Explanation Responses | Filing · EDGAR |
| May 9, 2023 | Open-market or private purchase | +850,000 | $16.00 | $13.6M | 4,787,914 See Explanation Responses | Filing · EDGAR |
| Dec 15, 2020 | Derivative converted | +2,004,581 | 2,004,581 See Explanation Responses | Filing · EDGAR | ||
| Dec 15, 2020 | Derivative converted | +833,333 | 2,837,914 See Explanation Responses | Filing · EDGAR | ||
| Dec 15, 2020 | Open-market or private purchase | +1,100,000 | $23.00 | $25.3M | 3,937,914 See Explanation Responses | Filing · EDGAR |
| Dec 15, 2020 | Derivative converted Series B Redeemable Convertible Preferred Stock | −2,004,581 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Dec 15, 2020 | Derivative converted Series C Redeemable Convertible Preferred Stock | −833,333 | 0 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 22, 2023 | Open-market or private sale | −110,756 | $9.90 | $1.1M | 641,010 See Explanation of Responses | Filing · EDGAR |
| Jun 22, 2023 | Open-market or private sale | −5,427,043 | $9.90 | $53.7M | 31,409,512 See Explanation of Responses | Filing · EDGAR |
| Jun 22, 2023 | Open-market or private sale | −5,236,006 | $9.90 | $51.8M | 30,303,871 See Explanation of Responses | Filing · EDGAR |
| Jun 22, 2023 | Open-market or private sale | −2,226,195 | $9.90 | $22M | 12,884,307 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 22, 2022 | Derivative converted | −2,459,880 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Nov 22, 2022 | Derivative converted | −1,211,582 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Nov 2, 2022 | Open-market or private purchase | +567,532 | $10.08 | $5.7M | 2,459,880 See Explanation of Responses | Filing · EDGAR |
| Nov 2, 2022 | Open-market or private purchase | +279,530 | $10.08 | $2.8M | 1,211,582 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 15, 2022 | Open-market or private purchase Pre-Funded Warrants to Purchase Common Stock | +3,333,388 | $6.00 | $20M | 3,333,388 See Explanation of Responses | Filing · EDGAR |
| Jul 29, 2021 | Derivative converted | +3,388,777 | 3,388,777 See Explanation Responses | Filing · EDGAR | ||
| Jul 29, 2021 | Open-market or private purchase | +806,000 | $13.00 | $10.5M | 4,194,777 See Explanation Responses | Filing · EDGAR |
| Jul 29, 2021 | Derivative converted Series B Preferred Units | −21,578,387 | 0 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 11, 2022 | Derivative converted Series C-1 Preferred Stock | −4,870,536 | 0 See Explanation of Responses | Filing · EDGAR | ||
| Sep 9, 2022 | Open-market or private sale | −312,353 | $29.87 | $9.3M | 4,082,713 See Explanation of Responses | Filing · EDGAR |
| Sep 9, 2022 | Open-market or private sale | −156,463 | $30.90 | $4.8M | 3,926,250 See Explanation of Responses | Filing · EDGAR |
| Sep 9, 2022 | Open-market or private sale | −6,654 | $31.44 | $209K | 3,919,596 See Explanation of Responses | Filing · EDGAR |
| Sep 9, 2022 | Open-market or private sale | −147,502 | $29.87 | $4.4M | 1,927,968 See Explanation of Responses | Filing · EDGAR |
| Sep 9, 2022 | Open-market or private sale | −73,886 | $30.90 | $2.3M | 1,854,082 See Explanation of Responses | Filing · EDGAR |
| Sep 9, 2022 | Open-market or private sale | −3,142 | $31.44 | $99K | 1,850,940 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −80,715 | $27.28 | $2.2M | 4,789,821 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −108,631 | $28.16 | $3.1M | 4,681,190 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −159,026 | $29.14 | $4.6M | 4,522,164 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −15,996 | $30.59 | $489K | 4,506,168 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −111,102 | $32.23 | $3.6M | 4,395,066 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −38,116 | $27.28 | $1M | 2,261,884 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −51,298 | $28.16 | $1.4M | 2,210,586 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −75,096 | $29.14 | $2.2M | 2,135,490 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −7,554 | $30.59 | $231K | 2,127,936 See Explanation of Responses | Filing · EDGAR |
| Sep 8, 2022 | Open-market or private sale | −52,466 | $32.23 | $1.7M | 2,075,470 See Explanation of Responses | Filing · EDGAR |
| Jan 11, 2022 | Derivative converted | +4,870,536 | 4,870,536 See Explanation of Responses | Filing · EDGAR | ||
| Jan 11, 2022 | Open-market or private purchase | +2,300,000 | $19.00 | $43.7M | 2,300,000 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 18, 2022 | Open-market or private sale | −1,147,205 | $29.90 | $34.3M | 3,360,687 See Explanation of Responses | Filing · EDGAR |
| Mar 18, 2022 | Open-market or private sale | −101,795 | $29.90 | $3M | 298,205 See Explanation of Responses | Filing · EDGAR |
| Sep 17, 2021 | Derivative converted | +3,407,028 | 3,715,170 See Explanation of Responses | Filing · EDGAR | ||
| Sep 17, 2021 | Derivative converted | +678,985 | 4,394,155 See Explanation of Responses | Filing · EDGAR | ||
| Sep 17, 2021 | Derivative converted | +113,737 | 4,507,892 See Explanation of Responses | Filing · EDGAR | ||
| Sep 17, 2021 | Open-market or private purchase | +400,000 | $35.00 | $14M | 400,000 See Explanation of Responses | Filing · EDGAR |
| Sep 17, 2021 | Derivative converted Series E Preferred Stock | −3,407,028 | 0 See Explanation Responses | Filing · EDGAR | ||
| Sep 17, 2021 | Derivative converted Series F Preferred Stock | −678,985 | 0 See Explanation Responses | Filing · EDGAR | ||
| Sep 17, 2021 | Derivative converted Series G Preferred Stock | −113,737 | 0 See Explanation Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 2, 2022 | Other acquisition or disposition (see the filing) | −288,000,000 | 51,055,144 See Explanation of Responses | Filing · EDGAR | ||
| Mar 2, 2022 | Other acquisition or disposition (see the filing) Class C Common Stock | +288,000,000 | 288,000,000 See Explanation of Responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 14, 2020 | Open-market or private sale | −1,000,000 | $55.65 | $55.7M | 29,993,708 See explanation of responses | Filing · EDGAR |
| Nov 11, 2020 | Open-market or private sale | −2,500,000 | $49.52 | $123.8M | 30,993,708 See explanation of responses | Filing · EDGAR |
| Jan 28, 2020 | Open-market or private sale | −4,912,899 | $24.98 | $122.7M | 33,493,708 See explanation of responses | Filing · EDGAR |
| Jul 1, 2019 | Open-market or private purchase | +250,000 | $20.00 | $5M | 1,675,000 See explanation of responses | Filing · EDGAR |
| Jul 1, 2019 | Derivative converted | +18,908,945 | 20,583,945 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted | +15,524,350 | 36,108,295 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted | +2,007,740 | 38,116,035 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted | +290,572 | 38,406,607 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted Series D Preferred Stock | −18,908,945 | 0 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted Series E Preferred Stock | −15,524,350 | 0 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted Series F Preferred Stock | −2,007,740 | 0 See explanation of responses | Filing · EDGAR | ||
| Jul 1, 2019 | Derivative converted Series F-1 Preferred Stock | −290,572 | 0 See explanation of responses | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 12, 2018 | Open-market or private purchase Series A Participating Convertible Preferred Shares | +664,000 | $100.00 | $66.4M | 1,164,000 See Footnotes | Filing · EDGAR |
| Oct 16, 2017 | Open-market or private purchase Series A Participating Convertible Preferred Shares | +500,000 | $100.00 | $50M | 500,000 See Footnotes | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 18, 2019 | Open-market or private purchase | +6,666,667 | $1.50 | $10M | 105,952,381 See Footnotes | Filing · EDGAR |
| Dec 18, 2018 | Open-market or private purchase | +10,000,000 | $1.00 | $10M | 99,285,714 See Footnotes | Filing · EDGAR |
| Jun 5, 2018 | Open-market or private purchase | +14,285,714 | $1.75 | $25M | 89,285,714 See Footnotes | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 19, 2019 | Open-market or private purchase | +4,957 | $8.17 | $40K | 22,860,013 See Footnotes | Filing · EDGAR |
| Jun 18, 2019 | Open-market or private purchase | +6,706 | $8.21 | $55K | 22,855,056 See Footnotes | Filing · EDGAR |
| Jun 17, 2019 | Open-market or private purchase | +6,541 | $8.53 | $56K | 22,848,350 See Footnotes | Filing · EDGAR |
| Jun 14, 2019 | Open-market or private purchase | +7,144 | $7.91 | $57K | 22,841,809 See Footnotes | Filing · EDGAR |
| Jun 13, 2019 | Open-market or private purchase | +7,367 | $7.95 | $59K | 22,834,665 See Footnotes | Filing · EDGAR |
| Jun 12, 2019 | Open-market or private purchase | +7,500 | $8.30 | $62K | 22,827,298 See Footnotes | Filing · EDGAR |
| Jun 11, 2019 | Open-market or private purchase | +7,189 | $8.58 | $62K | 22,819,798 See Footnotes | Filing · EDGAR |
| Jun 10, 2019 | Open-market or private purchase | +7,500 | $8.35 | $63K | 22,812,609 See Footnotes | Filing · EDGAR |
| Jun 7, 2019 | Open-market or private purchase | +6,649 | $7.97 | $53K | 22,805,109 See Footnotes | Filing · EDGAR |
| Jun 6, 2019 | Open-market or private purchase | +7,082 | $8.00 | $57K | 22,798,460 See Footnotes | Filing · EDGAR |
| Jun 5, 2019 | Open-market or private purchase | +6,540 | $8.02 | $52K | 22,791,378 See Footnotes | Filing · EDGAR |
| Jun 4, 2019 | Open-market or private purchase | +7,500 | $7.59 | $57K | 22,784,838 See Footnotes | Filing · EDGAR |
| Jun 3, 2019 | Open-market or private purchase | +5,424 | $7.71 | $42K | 22,777,338 See Footnotes | Filing · EDGAR |
| May 31, 2019 | Open-market or private purchase | +5,071 | $7.70 | $39K | 22,771,914 See Footnotes | Filing · EDGAR |
| May 30, 2019 | Open-market or private purchase | +6,951 | $7.97 | $55K | 22,766,543 See Footnotes | Filing · EDGAR |
| May 30, 2019 | Open-market or private purchase | +300 | $8.91 | $3K | 22,766,843 See Footnotes | Filing · EDGAR |
| May 29, 2019 | Open-market or private purchase | +6,882 | $7.55 | $52K | 22,759,592 See Footnotes | Filing · EDGAR |
| May 28, 2019 | Open-market or private purchase | +3,807 | $7.68 | $29K | 22,752,710 See Footnotes | Filing · EDGAR |
| May 24, 2019 | Open-market or private purchase | +3,796 | $7.70 | $29K | 22,748,903 See Footnotes | Filing · EDGAR |
| May 23, 2019 | Open-market or private purchase | +4,802 | $7.76 | $37K | Filing · EDGAR | |
| May 22, 2019 | Open-market or private purchase | +5,033 | $8.06 | $41K | 22,740,305 See Footnotes | Filing · EDGAR |
| May 21, 2019 | Open-market or private purchase | +9,995 | $9,995.00 | $99.9M | 22,735,272 See Footnotes | Filing · EDGAR |
| May 20, 2019 | Open-market or private purchase | +8,285 | $7.98 | $66K | Filing · EDGAR | |
| May 20, 2019 | Open-market or private purchase | +1,715 | $8.39 | $14K | Filing · EDGAR | |
| May 17, 2019 | Open-market or private purchase | +6,200 | $7.36 | $46K | Filing · EDGAR | |
| May 16, 2019 | Open-market or private purchase | +5,408 | $6.79 | $37K | 22,709,077 See Footnotes | Filing · EDGAR |
| Oct 1, 2018 | Open-market or private purchase | +2,678,571 | $14.00 | $37.5M | 22,703,669 See Footnotes | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 13, 2016 | Derivative converted | +21,750,064 | 21,750,064 See explanation of responses | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted | +5,413,702 | 5,413,702 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted | +317,519 | 317,519 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted | +10,144,738 | 10,144,738 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted | +5,874,105 | 5,874,105 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted Class B Common Stock | −21,750,064 | 0 See explanation of responses | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted Class B Common Stock | −5,413,702 | 0 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted Class B Common Stock | −317,519 | 0 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted Class B Common Stock | −10,144,738 | 0 direct | Filing · EDGAR | ||
| Apr 13, 2016 | Derivative converted Class B Common Stock | −5,874,105 | 0 direct | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 8, 2016 | Derivative converted Series B Preferred Stock | −4,444,444 | 0 See explanation of responses | Filing · EDGAR | ||
| Feb 8, 2016 | Derivative converted Series B Preferred Stock | −4,444,444 | 0 direct | Filing · EDGAR | ||
| Feb 8, 2015 | Derivative converted | +1,709,401 | 1,709,401 See explanation of responses | Filing · EDGAR | ||
| Feb 8, 2015 | Open-market or private purchase | +1,000,000 | $16.00 | $16M | 2,709,401 See explanation of responses | Filing · EDGAR |
| Feb 8, 2015 | Open-market or private purchase | +20,407 | $18.00 | $367K | 2,729,808 See explanation of responses | Filing · EDGAR |
| Feb 8, 2015 | Derivative converted | +1,709,401 | 1,709,401 direct | Filing · EDGAR | ||
| Feb 8, 2015 | Open-market or private purchase | +256,986 | $16.00 | $4.1M | 256,986 direct | Filing · EDGAR |
| Feb 8, 2015 | Open-market or private purchase | +15,072 | $18.00 | $271K | 15,072 direct | Filing · EDGAR |
| Feb 8, 2015 | Open-market or private purchase | +481,567 | $16.00 | $7.7M | 481,567 direct | Filing · EDGAR |
| Feb 8, 2015 | Open-market or private purchase | +261,447 | $16.00 | $4.2M | 261,447 direct | Filing · EDGAR |
| Feb 8, 2015 | Open-market or private purchase | +5,335 | $18.00 | $96K | 266,782 direct | Filing · EDGAR |
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 20, 2014 | Open-market or private purchase | +17,600 | $22.73 | $400K | 1,791,536 See Explanation of Responses | Filing · EDGAR |
| Nov 20, 2014 | Open-market or private purchase | +17,600 | $22.73 | $400K | 538,711 direct | Filing · EDGAR |
| Nov 7, 2014 | Open-market or private purchase | +22,500 | $26.60 | $599K | 1,773,936 See Explanation of Responses | Filing · EDGAR |
| Nov 7, 2014 | Open-market or private purchase | +22,500 | $26.60 | $599K | 521,111 direct | Filing · EDGAR |
| Nov 3, 2014 | Open-market or private purchase | +1,200 | $25.17 | $30K | 1,751,436 See Explanation of Responses | Filing · EDGAR |
| Nov 3, 2014 | Open-market or private purchase | +1,200 | $25.17 | $30K | 498,611 direct | Filing · EDGAR |
| Oct 2, 2014 | Open-market or private purchase | +400,000 | $29.00 | $11.6M | 1,750,236 See Explanation of Responses | Filing · EDGAR |
| Oct 2, 2014 | Open-market or private purchase | +79,250 | $36.00 | $2.9M | 1,750,236 See Explanation of Responses | Filing · EDGAR |
| Oct 2, 2014 | Open-market or private purchase | +99,621 | $29.00 | $2.9M | 427,215 direct | Filing · EDGAR |
| Oct 2, 2014 | Open-market or private purchase | +5,840 | $36.00 | $210K | 25,054 direct | Filing · EDGAR |
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 9, 2025 | Form 4 | Inhibrx Biosciences INXB | Filing · EDGAR |
| Jul 1, 2025 | Form 4 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Feb 14, 2025 | Form 3 | Acuren TIC | Filing · EDGAR |
| Jan 31, 2025 | Form 144 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Jan 31, 2025 | Form 4 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Jun 18, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Jun 18, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Jun 7, 2024 | Form 3 | Inhibrx Biosciences INXB | Filing · EDGAR |
| Jun 3, 2024 | Form 4 | Inhibrx | Filing · EDGAR |
| Mar 20, 2024 | Form 3 | Standard Biotools | Filing · EDGAR |
| Mar 7, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Mar 7, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Mar 1, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Mar 1, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Feb 28, 2024 | Form 4 | RayzeBio | Filing · EDGAR |
| Feb 28, 2024 | Form 4 | RayzeBio | Filing · EDGAR |
| Jan 5, 2024 | Form 4 | 4D Molecular Therapeutics | Filing · EDGAR |
| Jan 4, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Jan 4, 2024 | Form 4 | APi Group | Filing · EDGAR |
| Jan 2, 2024 | Form 144 | APi Group | Filing · EDGAR |
| Sep 21, 2023 | Form 4 | RayzeBio | Filing · EDGAR |
| Sep 21, 2023 | Form 4 | RayzeBio | Filing · EDGAR |
| Sep 14, 2023 | Form 3 | RayzeBio | Filing · EDGAR |
| Sep 14, 2023 | Form 3 | RayzeBio | Filing · EDGAR |
| Aug 30, 2023 | Form 4 | Inhibrx | Filing · EDGAR |
| Jul 19, 2023 | Form 4 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Jun 26, 2023 | Form 4 | Roivant Sciences | Filing · EDGAR |
| May 11, 2023 | Form 4 | 4D Molecular Therapeutics | Filing · EDGAR |
| Nov 25, 2022 | Form 4 | Frazier Lifesciences Acquisition | Filing · EDGAR |
| Nov 17, 2022 | Form 4 | Rallybio | Filing · EDGAR |
| Nov 4, 2022 | Form 4 | Frazier Lifesciences Acquisition | Filing · EDGAR |
| Nov 4, 2022 | Form 3 | Frazier Lifesciences Acquisition | Filing · EDGAR |
| Oct 12, 2022 | Form 4 | Inhibrx | Filing · EDGAR |
| Sep 9, 2022 | Form 4 | Amylyx Pharmaceuticals | Filing · EDGAR |
| Mar 22, 2022 | Form 4 | PROCEPT BioRobotics | Filing · EDGAR |
| Mar 4, 2022 | Form 4 | Ginkgo Bioworks Holdings | Filing · EDGAR |
| Jan 13, 2022 | Form 4 | Amylyx Pharmaceuticals | Filing · EDGAR |
| Jan 11, 2022 | Form 3 | Amylyx Pharmaceuticals | Filing · EDGAR |
| Jan 5, 2022 | Form 4 | APi Group | Filing · EDGAR |
| Oct 1, 2021 | Form 3 | Roivant Sciences | Filing · EDGAR |
| Sep 23, 2021 | Form 3 | Ginkgo Bioworks Holdings | Filing · EDGAR |
| Sep 21, 2021 | Form 4 | PROCEPT BioRobotics | Filing · EDGAR |
| Sep 14, 2021 | Form 3 | PROCEPT BioRobotics | Filing · EDGAR |
| Sep 3, 2021 | Form 4 | FIGS | Filing · EDGAR |
| Aug 2, 2021 | Form 4 | Rallybio | Filing · EDGAR |
| Jul 29, 2021 | Form 3 | Rallybio | Filing · EDGAR |
| Jun 7, 2021 | Form 3 | FIGS | Filing · EDGAR |
| Dec 17, 2020 | Form 4 | 4D Molecular Therapeutics | Filing · EDGAR |
| Dec 16, 2020 | Form 4 | Adaptive Biotechnologies | Filing · EDGAR |
| Dec 10, 2020 | Form 3 | 4D Molecular Therapeutics | Filing · EDGAR |
| Dec 3, 2020 | Form 4 | Zentalis Pharmaceuticals | Filing · EDGAR |
| Nov 13, 2020 | Form 4 | Adaptive Biotechnologies | Filing · EDGAR |
| Aug 28, 2020 | Form 4 | Inhibrx | Filing · EDGAR |
| Aug 25, 2020 | Form 4 | Inhibrx | Filing · EDGAR |
| Aug 25, 2020 | Form 3 | Inhibrx | Filing · EDGAR |
| Apr 28, 2020 | Form 3 | APi Group | Filing · EDGAR |
| Apr 8, 2020 | Form 4 | Zentalis Pharmaceuticals | Filing · EDGAR |
| Apr 3, 2020 | Form 3 | Zentalis Pharmaceuticals | Filing · EDGAR |
| Jan 30, 2020 | Form 4 | Adaptive Biotechnologies | Filing · EDGAR |
| Jul 12, 2019 | Form 4 | Arbutus Biopharma | Filing · EDGAR |
| Jul 12, 2019 | Form 4 | Axovant Gene Therapies | Filing · EDGAR |
| Jul 12, 2019 | Form 4 | Myovant Sciences | Filing · EDGAR |
| Jul 12, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Jul 2, 2019 | Form 4 | Adaptive Biotechnologies | Filing · EDGAR |
| Jun 28, 2019 | Form 4 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Jun 27, 2019 | Form 3 | BridgeBio Pharma BBIO | Filing · EDGAR |
| Jun 26, 2019 | Form 3 | Adaptive Biotechnologies | Filing · EDGAR |
| Jun 19, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Jun 14, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Jun 13, 2019 | Form 4 | Myovant Sciences | Filing · EDGAR |
| Jun 11, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Jun 6, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Jun 3, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| May 29, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| May 23, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| May 20, 2019 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Mar 19, 2019 | Form 4 | Axovant Gene Therapies | Filing · EDGAR |
| Dec 20, 2018 | Form 4 | Axovant Gene Therapies | Filing · EDGAR |
| Oct 3, 2018 | Form 4 | Urovant Sciences | Filing · EDGAR |
| Sep 26, 2018 | Form 3 | Urovant Sciences | Filing · EDGAR |
| Jun 7, 2018 | Form 4 | Axovant Gene Therapies | Filing · EDGAR |
| Apr 5, 2018 | Form 4 | Myovant Sciences | Filing · EDGAR |
| Jan 16, 2018 | Form 4 | Arbutus Biopharma | Filing · EDGAR |
| Oct 17, 2017 | Form 4 | Arbutus Biopharma | Filing · EDGAR |
| Oct 26, 2016 | Form 3 | Myovant Sciences | Filing · EDGAR |
| Jul 13, 2016 | Form 3 | Arbutus Biopharma | Filing · EDGAR |
| Jul 13, 2016 | Form 3 | Axovant Gene Therapies | Filing · EDGAR |
| Apr 15, 2016 | Form 4 | First Data | Filing · EDGAR |
| Feb 9, 2016 | Form 4/A | Editas Medicine | Filing · EDGAR |
| Feb 8, 2016 | Form 4 | Editas Medicine | Filing · EDGAR |
| Feb 2, 2016 | Form 3 | Editas Medicine | Filing · EDGAR |
| Oct 15, 2015 | Form 3 | First Data | Filing · EDGAR |
| Nov 24, 2014 | Form 4 | Wayfair | Filing · EDGAR |
| Nov 12, 2014 | Form 4 | Wayfair | Filing · EDGAR |
| Nov 5, 2014 | Form 4 | Wayfair | Filing · EDGAR |
| Oct 6, 2014 | Form 4 | Wayfair | Filing · EDGAR |
| Oct 2, 2014 | Form 3 | Wayfair | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.
